Roadmap
A Brighter Future In Cancer
At GenLumina, we’re focused on developing light-activated cancer treatments. By combining our nanocluster technology with antibodies, biomarkers, peptides and advanced imaging techniques we aim to precisely target and treat cancer cells.
Current focus Areas
Our current research explores multiple cancer indications, focusing on integrating biomarkers, peptides, and imaging techniques to identify and localize specific cancer types. By combining these with our light-activated nanoclusters, we ensure the treatment targets only cancer cells, leaving healthy tissue unharmed.
Colorectal cancer Treatment
Starting with colorectal cancer, we are proving the efficacy of our light-activated technology in real-world applications.
Expanding to Other Cancer Types
We are utilizing our platform’s adaptability to expand to a wide range of cancers, aiming to make a greater impact on patients’ lives.
“Given the potential of GenLumina’s light-activated therapy to target tumors effectively, improve surgical precision, and minimize collateral tissue damage, I believe this technology holds great promise for advancing cancer treatment, particularly for colorectal, ovarian, and pancreatic cancers.”
Dr. Alexander Vahrmeijer
LUMC, Surgical Oncologist
Collaborate With Us
Partners
We’re seeking partners for proof-of-concept research in various cancers. Our customizable DNA technology integrates with imaging techniques for precise cancer localization and targeted treatments, making it ideal for use with antibodies, peptides, and other markers.
Specialists
As we approach clinical trials, we’re seeking partners to help bring our treatments to patients. We’re looking for leaders in oncology and pharmaceutical development to collaborate on early-stage clinical trials.
Integration
We are committed to making these treatments accessible to patients worldwide. Our platform can integrate with existing cancer treatments, such as radiotherapy, immunotherapy, and surgery to improve overall patient outcomes.
Learn more
“A more effective photodynamic treatment would make tens of thousands of surgical procedures with complications, disturbing scars, and multiple hospital visits unnecessary every year.”
Remco van Doorn
LUMC, Dermatologist
“A better, more tumor-selective and less toxic treatment for skin cancers is eagerly awaited. The light-activated DNA-silver constructs provide a new opportunity to explore highly selective treatment of superficial cancers.”
Dr. Wouter Vogel
NKI, Nuclear Dermatologist
You can count on us for using our drug to push the boundaries of
what is possible in precision oncology.